icer white paper affordable access to glp-1 obesity medications 2025 GLP-1 Trends: Costs & Coverage Barrier Amid Uncertainty-mvanhaasteren.nl Outlook for Obesity in 2026:
Description
Looking for smoothies that fit your GLP-1 lifestyle
Were looking forward to catching up with industry leaders, researchers, and sponsors to discuss how we can drive progress together
Well continue expanding access to the latest innovations to make high-quality care easier for patients:
Ozempic may be more expensive and harder to find now that compounded semaglutide isn't available
It is not approved for any of these yet, but the intent is clearly broader metabolic health, not just weight loss
Compounded semaglutide is now banned
